WO1998041652A2 - Dna zum nachweis von veränderungen des chromosoms 7 - Google Patents
Dna zum nachweis von veränderungen des chromosoms 7 Download PDFInfo
- Publication number
- WO1998041652A2 WO1998041652A2 PCT/DE1998/000782 DE9800782W WO9841652A2 WO 1998041652 A2 WO1998041652 A2 WO 1998041652A2 DE 9800782 W DE9800782 W DE 9800782W WO 9841652 A2 WO9841652 A2 WO 9841652A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- chromosome
- minutes
- cells
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to DNA, which is used to detect changes in chromosome 7, and to polypeptides encoded by such DNA.
- the invention further relates to antibodies which are directed against the polypeptides. Furthermore, it relates to the use of the DNA and the polypeptides and a kit suitable for detecting a change in chromosome 7.
- a loss of chromosome 7 (-7) or a deletion of its long arm (7q-) are common chromosomal changes in myeloid diseases, especially in therapy-related myelodysplastic sydrome and myeloid leukemia. These diseases (-7 / 7q-) are characterized by a high susceptibility to infections, a weak response to chemotherapy and short survival times.
- Chromosomal changes in myeloid diseases are detected using the chromosome banding technique.
- changes on the chromosomal level can only be detected in dividable cells. Their resolving power is only in the range of several megabases. This only allows changes between chromosomal bands, but not within a chromosomal band, such as deletions, to be detected.
- the present invention is therefore based on the object of providing a means by which changes in chromosome 7 can be demonstrated while avoiding the above disadvantages. Another task is to provide a means by which such changes or their consequences can be corrected if necessary.
- the present invention thus relates to a DNA which is suitable for detecting a change in chromosome 7, in particular the chromosomal band 7q22.
- a DNA is selected from:
- the present invention is based on the knowledge of the applicant that myeloid diseases, in particular myeloid leukemia, have deletions and / or translocations in the chromosomal band 7q22.
- myeloid diseases in particular myeloid leukemia
- myeloid leukemia have deletions and / or translocations in the chromosomal band 7q22.
- the applicant has also recognized that these chromosomal changes can be detected by a DNA selected from:
- a DNA of (c) whose sequence is different from that of Fig. 1 by one or more base pairs can be obtained by conventional methods. It is advantageous to use the DNA with the sequence of FIG. 1 for screening a human gene or gene expression library from chromosome 7q22. The latter library is useful if the DNA of FIG. 1 is a cDNA, which is also preferred according to the invention. Positive clones are used for hybridization with the DNA of someone suffering from a myeloid disease. used by a healthy person. Clones reacting differently represent a DNA of (c). This can have a sequence which differs from that of FIG. 1 by one or more base pairs.
- a DNA according to the invention has a base sequence with which each of the DNAs of (a) - (c) hybridizes.
- hybridization indicates conventional conditions, in particular a hybridization temperature of approximately 20 ° C. below the melting point of the DNA sample used. Conventional methods can be used to provide such a DNA according to the invention. It is convenient to go through the DNAs of (a) - (c)
- a DNA according to the invention is most suitable for detecting a change in chromosome 7, in particular in chromosomal band 7q22. Usual methods can be used for this. It is favorable to use the DNA according to the invention for an in situ hybridization reaction with the DNA of the body sample to be examined. Any sample of a body containing cells, in particular bone marrow or blood, should be mentioned as a body sample.
- an in situ hybridization reaction reference is made to the example below and the work of Lichter, P. et al., Science 247, (1 990), 64.
- a DNA of (c) according to the invention can be present in an expression vector.
- examples of such are known to the person skilled in the art.
- an expression vector for E. coli these are, for example, pGEMEX, pUC derivatives, pGEX-2T, pQE-8 and pet3d.
- pY1 00 and Ycpad 1 For expression in yeast, for example, pY1 00 and Ycpad 1 should be mentioned, while for expression in animal cells, for example, pKCR, pEFBOS, cDM8 and pCEV4 must be specified.
- the baculovirus expression vector pAcSGHisNT-A is particularly suitable for expression in insect cells.
- suitable cells in order to express a DNA of (c) present according to the invention and present in an expression vector.
- suitable cells include the E. coli strains HB101, DH 1, x1 776, JM 101, JM 109, SG 1 3009 and BL21, the yeast strain Saccharomyces cerevisiae and the animal cells L, 3T3, FM3A, CHO, COS, Vero and HeLa and the insect cells sf9).
- Fusion polypeptide can be expressed.
- Another object of the present invention is an antibody directed against an above polypeptide or fusion polypeptide.
- Such an antibody can be produced by conventional methods. It can be polyclonal or monoclonal. For its production, it is favorable to immunize animals, in particular rabbits or chickens for a polyclonal and mice for a monoclonal antibody, with an above (fusion) polypeptide.
- the animals can be boosted further using the same (fusion) polypeptide.
- the polyclonal antibody can then be obtained from the serum or egg yolk of the animals.
- animal spleen cells are fused with myeloma cells.
- the present invention it is possible to detect changes in chromosome 7, in particular the chromosomal band 7q22. Such sales Changes can be found in a wide variety of diseases, especially myeloid leukemia.
- the present invention is therefore very well suited for the diagnosis of such diseases.
- the present invention provides polypeptides which are often missing or changed in the diseases mentioned. Especially in relation to myeloid leukemia, these polypeptides are of great importance as putative tumor suppressors.
- the present invention makes it possible to proceed therapeutically with these diseases.
- a cDNA of (c) according to the invention if it is present in a gene transfer vector.
- Such vectors are known. Examples include virus vectors such as retrovirus, adenovirus, vaccinia virus or adeno-associated virus vectors.
- the present invention provides antibodies which react with the polypeptides mentioned. With these antibodies it is possible to monitor the therapy with the polypeptides.
- the present invention provides means which, for the first time, enable sensitive and selective examinations at the genomic level in the most diverse diseases, in particular myeloid diseases
- the present invention also provides a kit.
- This contains one or more DNAs, polypeptides and / or antibodies according to the invention. It also contains common additives such as carriers, buffers, solvents and controls.
- the kit is also the subject of the present invention. Brief description of the drawing:
- Fig. 1 shows the base sequence, which is from a DNA of the invention
- Mononuclear cells are isolated from approximately 5 ml of heparinized blood (20 IU heparin / ml) or 5 ml of heparinized bone marrow by Ficoll-Hypaque density gradient centrifugation (Ficoll-Hypaque, Seromed). The cells are then incubated in hypotonic solution (approx. 1 x 10 6 -
- Bacterial clones which contain the DNA of (a) or (b) are first spread on agar plates (LB medium).
- the DNA of (a) or (b) is obtained with the DNA from Qiagen (Qiagen Inc., Ghatsworth,
- the size of the DNA is crucial for achieving good hybridization signals.
- a length between 200 and 500 base pairs is regarded as the optimum. This length range is determined by individually adjusting the DNAse I concentration and the reaction time for nick translation reached.
- BSA bovine serum albumin
- DNAse I stock solution 3 mg DNAse I in 0.5 ml 0.3 M NaCI + 0.5 ml glycerol, diluted 1: 1000 (Boehringer)
- E. coli DNA polymerase I 10,000 units / ml (New England Biolabs, Beverly, MA).
- E.coli DNA polymerase l 20 units - ad 100 ul total volume with distilled water.
- reaction vessels After incubation for at least 45 minutes at 15 ° C, the reaction vessels are placed on ice. An aliquot (approx. 8 ⁇ l) is taken after
- the interphase cells can be incubated on the slide with pepsin (Sigma) (2 mg / ml in 0.01 N HCl, 5 minutes at 37 ° C). This was followed by a washing step (1 x PBS, 5 minutes at room temperature), post-fixation with 2% paraformaldehyde (Sigma) (5 minutes on ice), and again
- wash step (1 x PBS, 10 minutes).
- the cells are then dehydrated in an alcohol series of increasing concentration (70%, 90%, 100% ethanol, each about 10 minutes).
- the preparations are preheated at 60 ° C for about 10-20 minutes.
- the hybridization mixture contains approx. 1 50-250 ng labeled sample DNA, 10 ⁇ g Cot-1 DNA fraction (BRL / Life Technologies, Gaitherburg, MD) and 10 ⁇ g herring sperm DNA (Boehringer Mannheim).
- Cot-1 fraction as competitor DNA, the hybridization of the highly repetitive sequence contained in the sample DNA is effectively suppressed.
- the chromosomal DNA is denatured on the slide for 2 minutes at 70 ° C in 70% deionized formamide, 2-x SSC (pH 7.0). This is immediately followed by dehydration in an ice-cold alcohol series of increasing concentration (70%, 90%, 100% ethanol, 5 minutes each).
- the preparations After incubation in a moist chamber (30 minutes at 37 ° C), the preparations are washed 3 times in 4xSSC / 0.1% Tween 20 (5 minutes each at 42 ° C). The preparations are counter-stained with 4,6-diamidino-2-phenylindole-dihydrochloride [DAPI (Sigma), 200 ng / ml in 2xSSC] (5-1 0 minutes at room temperature on a shaker) and then in 2xSSC / 0, 05% Tween 20 washed (3 minutes on a shaker). The washing steps after detection and counterstaining are carried out in light-protected cuvettes.
- DAPI 4,6-diamidino-2-phenylindole-dihydrochloride
- an antifade solution e.g. Pipette 20 mM Tris-HCl, pH 8.0, 90% glycerol, 2.3% 1, 4 diazabicyclo- (2.2.2.) Octane (DABCO, Sigma) and cover with a 24x36 mm cover slip.
- DABCO diazabicyclo- (2.2.2.) Octane
- the microscopic evaluation of the preparations determines the number of signals from at least 100 cell nuclei in the hybridization area.
- Microscopes equipped for epifluorescence microscopy with filter sets for DAPI, Pl, Cy3 and FITC are used for analysis.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19710926.8 | 1997-03-15 | ||
DE19710926A DE19710926C2 (de) | 1997-03-15 | 1997-03-15 | DNA zum Nachweis von Veränderungen des Chromosoms 7 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998041652A2 true WO1998041652A2 (de) | 1998-09-24 |
WO1998041652A3 WO1998041652A3 (de) | 1998-12-17 |
Family
ID=7823584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1998/000782 WO1998041652A2 (de) | 1997-03-15 | 1998-03-13 | Dna zum nachweis von veränderungen des chromosoms 7 |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE19710926C2 (de) |
WO (1) | WO1998041652A2 (de) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997008339A1 (en) * | 1995-08-25 | 1997-03-06 | Dade International Inc. | Chronic myelogenous leukemia diagnostic assay |
-
1997
- 1997-03-15 DE DE19710926A patent/DE19710926C2/de not_active Expired - Fee Related
-
1998
- 1998-03-13 WO PCT/DE1998/000782 patent/WO1998041652A2/de active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997008339A1 (en) * | 1995-08-25 | 1997-03-06 | Dade International Inc. | Chronic myelogenous leukemia diagnostic assay |
Non-Patent Citations (6)
Title |
---|
BEAU M ET AL: "Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases" BLOOD, Bd. 88, Nr. 6, 15. September 1996, Seiten 1930-5, XP002080798 * |
EMBL Database Entry HSAC117 Accession number AC000117; 14 February 1997; Maggi, L. et al.;"Human BAC clone RG062A19 from 7q22; HTGS phase 3, complete sequence XP002080802 * |
FISCHER K ET AL: "Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7Q22 in myeloid leukemias" BLOOD, Bd. 88, Nr. (10 Suppl. 1 part 1-2 ), 6. - 10. Dezember 1996, Seite 65a XP002080797 * |
JOHNSON E ET AL: "Monosomy 7 and 7q- associated with myeloid malignancy" BLOOD REVIEWS, Bd. 11, Nr. 1, M{rz 1997, Seiten 46-55, XP002080799 * |
LEWIS ET AL: "Molecular characterization of the 7Q deletion in myeloid disorders" BRITISH JOURNAL OF HAEMATOLOGY, Bd. 93, Nr. 1, 1996, Seiten 74-80, XP002080800 * |
OSCIER D ET AL: "Structural abnormalities of chromosome 7Q vin chronic lymphoproliferative disorders" CANCER GENETICS AND CYTOGENETICS, Bd. 92, Nr. 1, November 1996, Seiten 24-27, XP002080801 * |
Also Published As
Publication number | Publication date |
---|---|
DE19710926A1 (de) | 1998-09-17 |
DE19710926C2 (de) | 1999-11-04 |
WO1998041652A3 (de) | 1998-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69333315T2 (de) | Säugetier-rezeptoren für das melanocyten-stimulierendes hormon und deren verwendungen | |
WO1999022000A1 (de) | Inhibitor-protein des wnt-signalwegs | |
DE69334146T2 (de) | Peptide mit gdp-austauschfaktorartiger wirkung, dafür kodierende nukleinsäuresequenzen, ihre herstellung und verwendung | |
DE19824230A1 (de) | Neues Endometriose-assoziiertes Gen | |
DE69433915T2 (de) | MDC-Proteine und dafür kodierende DNS | |
EP1588172A2 (de) | Verfahren zur identifizierung bhs-spezifischer proteine und fragmente davon | |
DE69628936T2 (de) | Test zur identifikation von inhibitoren der interaktion zwischen p53 und dm2 proteinen | |
DE19710926C2 (de) | DNA zum Nachweis von Veränderungen des Chromosoms 7 | |
DE69333803T2 (de) | Polypeptide mit opioider rezeptor-aktvität, für sie kodierende nukleinsäuren und ihre verwendungen | |
DE19521046C1 (de) | Protein mit DNase-Aktivität | |
DE69832156T2 (de) | Zusammensetzungen des synaptischen Aktivierungsproteins und Verfahren | |
EP0941336A2 (de) | Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen | |
DE10009119A1 (de) | Vertebraten Globin | |
WO1993013205A1 (de) | Neuroblastom-assoziiertes regulator-gen | |
DE19856882C1 (de) | Spermatogenese-Protein | |
DE19650758C1 (de) | PKD1-Fragmente mit Bindungsregionen für PKD1-spezifische Antikörper | |
DE10244502B4 (de) | Molekulargewichtsmarker für Proteine und Verfahren zu dessen Herstellung | |
DE69434333T2 (de) | Methoden unter verwendung von eaa3 oder eaa4 rezeptoren | |
DE19816186A1 (de) | GDNF-kodierende DNA, Teile davon und GDNF-Varianten | |
DE19825621C2 (de) | Protein zur Regulation von Apoptose | |
DE19730997C1 (de) | SRCR Domäne-enthaltendes Protein | |
WO2000015784A2 (de) | Humaner un muriner g-protein gekoppelter rezeptor edg6 (endothelial differentiation gen) und seine verwendung | |
DE69827808T2 (de) | Protease-ähnliches protein | |
DE19847364C1 (de) | Tumor-Protein | |
DE19644501A1 (de) | GABA¶A¶-Rezeptoruntereinheit epsilon-verwandtes Protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998540029 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |